A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

This is a multicenter, international, open-label, single arm, Phase 2 study designed to
evaluate the efficacy and safety of PCI-32765 in subjects with relapsed/refractory CLL or
SLL with del 17p. All subjects will receive PCI-32765 until disease progression or
unacceptable toxicity occurs.

Key Inclusion Criteria:

- Documentation of del (17p13.1)

- Must have relapsed or refractory CLL/SLL after receiving at least 1 prior line of
systemic therapy.

- Measurable nodal disease by computed tomography (CT)

Key Exclusion Criteria:

- History or current evidence of Richter's transformation or prolymphocytic leukemia

- Prior hematologic stem cell transplantation <6 months from study enrollment or any
ongoing GVHD

- Prior exposure to PCI-32765